Panacos Pharmaceuticals, Inc. (PANC) Stock Price & Analysis

Panacos Pharmaceuticals, Inc. (PANC) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 200 shares. Market capitalization is $321,841, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 00:59 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PANC.md

Key facts (PANC)

Analysts (PANC)

Consensus None.

Total return (dividends reinvested) (PANC)

1Y (from 2025-10-24)5Y (from 2021-10-25)
Total return+0.0%+0.0%
S&P 500 (SPY)+14.0%+76.9%
Per year+0.0%+0.0%
Volatility (annualized)0.0%145.6%
Max drawdown+0.0% (→)-90.0% (Oct 2021→Nov 2022)

PANC analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter———$0—
Next quarter (ends Mar 2009)———$0—
Current fiscal year (ends Dec 2008)———$0—
Next fiscal year———$0—

Key Statistics (as of October 24, 2026 at 00:59 UTC)

PriceUSD 0
Change▲ 0.00% (up)
Previous CloseUSD 0
OpenUSD 0
Day RangeUSD 0 – 0
52-Week RangeUSD 0 – 0
Volume200 shares
Market Cap$321,841
ExchangePNK

Technical Analysis (PANC)

Nexqual's technical model rates PANC "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 24, 2026 at 00:59 UTC.

Overall SignalSTRONG SELL
RSI (14)100 (overbought)
vs SMA50Below (USD 0)
MACD0 (negative)

Analyst Ratings (PANC)

Wall Street analysts rate PANC "None", per Nexqual as of October 24, 2026 at 00:59 UTC.

Consensus RatingNone

Earnings (PANC)

Recent Earnings History

QuarterActual vs Estimate
2008-09-30USD -0.15 vs est -0.2 ▲ beat
2008-06-30USD -0.18 vs est -0.18 ▲ beat
2008-03-31USD -0.16 vs est -0.19 ▲ beat
2007-12-31USD -0.17 vs est -0.2 ▲ beat

Source: Nexqual, October 24, 2026 at 00:59 UTC.

Financials & Fundamentals (PANC)

Total Revenue$99,000
Revenue Growth (latest quarter, YoY)-20.00%
Gross Margin+100.00%
Operating Margin-31545.83%
Profit Margin+0.00%
ROE-168.83%
Debt / Equity3.45
Current Ratio2.15
Total Cash$26.89M
Total Debt$18.21M

Source: Nexqual, October 24, 2026 at 00:59 UTC.

Financial Health Score (PANC)

Nexqual rates Panacos Pharmaceuticals, Inc.'s overall financial health "Critical" across five dimensions, as of October 24, 2026 at 00:59 UTC.

GrowthCritical — Revenue -37% YoY (annual), sharp decline
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetWeak — $27M cash vs $18M debt, net cash position
Cash FlowWeak — Operating cash flow -$31M (TTM)
EfficiencyCritical — ROE -169%, ROA -52.6%

Ownership (PANC)

Insider Ownership+0.00%
Institutional Ownership+0.00%
Shares Outstanding0

Source: Nexqual, October 24, 2026 at 00:59 UTC.

Peers & Related Stocks

SymbolNamePriceChange
LGNDLigand Pharmaceuticals IncorporUSD 303.53▼ 1.39%
RYTMRhythm Pharmaceuticals, Inc.USD 89.27▼ 1.79%
IOVAIovance Biotherapeutics, Inc.USD 14.09▼ 0.35%
PRAXPraxis Precision Medicines, IncUSD 252.96▼ 2.3%
IONSIonis Pharmaceuticals, Inc.USD 42.93▼ 2.23%
AXSMAxsome Therapeutics, Inc.USD 145.04▼ 7.07%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 00:59 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt